published meta-analysis   sensitivity analysis   studies

CoVLP (MT-2766, Medicago) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias symptomatic Covid-19detailed resultsHager (phase 3), 2022 0.31 [0.21; 0.44] 0.31[0.21; 0.44]Hager (phase 3), 202210%NAnot evaluable severe COVID-19 occurrencedetailed resultsHager (phase 3), 2022 0.17 [0.01; 3.33] 0.17[0.01; 3.33]Hager (phase 3), 202210%24,141NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-04-27 12:24 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1265 - roots T: 290